1.07
-0.07(-6.14%)
Currency In USD
Address
210 Broadway
Boston, MA 02139
United States of America
Phone
401 426 4664
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
December 21, 2021
| Name | Title | Pay | Year Born |
| Mr. Thomas H. Jensen | Founder, Chief Executive Officer & Director | 791,600 | 1978 |
| Dr. Steen Meier Knudsen Ph.D. | Founder & Chief Scientific Officer | 197,311 | 1961 |
| Dr. Jeremy R. Graff Ph.D. | President & Chief Development Officer | 269,174 | 1970 |
| Mr. Jeffrey S. Ervin M.B.A. | Chief Financial Officer | 0 | 1978 |
| Dr. Jose L. Iglesias M.D. | Consultant Chief Medical Officer | 0 | 1957 |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.